Lixisenatide may have potential as a therapeutic agent for reducing oxidative stress and inflammation (GLP-1 receptor independent) in the early stages of diabetic retinopathy, which could potentially prevent or delay the development of more severe forms of the disease. This evidence concerns the gene GLP1R and diabetic retinopathy.